Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
About electroCore, Inc. (NASDAQ: ECOR)
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to advancing health and wellness through its innovative non-invasive vagus nerve stimulation (nVNS) technology platform. Headquartered in the United States, electroCore is at the forefront of the rapidly growing field of neuromodulation, offering a range of solutions for medical conditions and general wellness. The company’s technology is designed to address unmet needs in neurology, psychiatry, gastroenterology, and other medical fields, while also catering to consumer wellness and performance enhancement markets.
Core Business Areas
electroCore’s core focus lies in the development, commercialization, and distribution of nVNS-based medical devices and wellness products. Its flagship product, gammaCore™, has received FDA clearance for multiple indications, including the acute and preventive treatment of migraines and cluster headaches in adults and adolescents. The company also offers Truvaga™ and TAC-STIM™, which target consumer wellness and military applications, respectively, enhancing focus, energy, and cognitive performance.
Product Portfolio
- gammaCore™: A prescription device for managing migraines, cluster headaches, and other neurological conditions. gammaCore is approved for use in the U.S., Europe, and select international markets.
- Truvaga™: A consumer-focused handheld device designed to promote stress relief, improve sleep, and enhance overall well-being.
- TAC-STIM™: Developed in collaboration with the U.S. Department of Defense, this portable device is tailored for military personnel, improving readiness, focus, and fatigue management.
- Quell®: Following its acquisition of NeuroMetrix, electroCore has expanded its portfolio to include Quell, a wearable neuromodulation platform targeting chronic pain and fibromyalgia.
Market Position
electroCore operates at the intersection of healthcare, wellness, and technology, positioning itself as a leader in non-invasive neuromodulation. By combining clinical-grade devices with consumer-oriented solutions, the company addresses a diverse range of markets, including medical professionals, patients, military personnel, and wellness enthusiasts. Its patented technology and FDA clearances provide a competitive edge, while its collaborations with institutions like the U.S. Air Force Research Laboratory underscore its commitment to innovation.
Revenue Model and Global Reach
electroCore generates revenue through direct sales, licensing agreements, and partnerships with healthcare providers and government institutions. The company has a global presence, with offices in the U.S., Germany, the U.K., Italy, Australia, and Canada, enabling it to serve both domestic and international markets effectively.
Research and Development
Innovation is central to electroCore’s mission. The company invests heavily in clinical trials and research collaborations to expand the applications of nVNS technology. Recent studies have demonstrated the efficacy of nVNS in accelerating learning, improving cognitive performance, and managing conditions like PTSD and chronic pain.
Competitive Landscape
In the bioelectronic medicine space, electroCore competes with other neuromodulation companies but differentiates itself through its non-invasive approach, robust intellectual property portfolio, and diverse product applications. Its focus on both clinical and consumer markets further sets it apart from competitors.
Significance in the Industry
As a pioneer in bioelectronic medicine, electroCore is redefining how neurological and psychiatric conditions are managed. Its commitment to evidence-based solutions and its ability to bridge the gap between medical and consumer applications make it a significant player in the industry.
Conclusion
electroCore, Inc. exemplifies innovation in bioelectronic medicine, offering transformative solutions for medical and wellness needs. Its focus on non-invasive, user-friendly technology and its dedication to research and development position it as a key contributor to the future of healthcare and human performance.
electroCore, Inc. (Nasdaq: ECOR) announced a reverse stock split of its common stock at a ratio of 1-for-15, effective February 15, 2023. This decision follows stockholder approval on February 13, 2023, to amend the Company’s certificate of incorporation, allowing a split ratio between 1-for-5 and 1-for-50. The split aims to increase the stock price to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. After the split, stockholder ownership percentages will remain unchanged, except for fractional shares, which will be compensated with cash based on the closing price on February 14, 2023.
electroCore (Nasdaq: ECOR) reported a record revenue of approximately $8.5 million for the full year 2022, marking a 57% increase from 2021. The company also achieved $2.5 million in revenue for the fourth quarter, a 68% growth year-over-year. Key revenue drivers included about $5.1 million from government channels, showing a 56% growth compared to 2021, and $1.7 million from U.S. commercial channels, reflecting a 158% increase. The firm ended 2022 with approximately $18.0 million in cash and equivalents, down from $21.9 million in Q3.
electroCore, Inc. (Nasdaq: ECOR) has launched a new wellness product, TruvagaTM, available in the U.S. via its ecommerce site, www.truvaga.com. This handheld, non-invasive vagus nerve stimulator is designed to promote general wellbeing through stress reduction, requiring only two-minute sessions without the need for apps or chargers. CEO Dan Goldberger emphasized that Truvaga is part of the company's strategy to enhance accessibility to vagus nerve stimulation technology. This move aligns with electroCore's focus on improving health outcomes through innovative therapies.
electroCore (Nasdaq: ECOR) announced the issuance of two new patents by the USPTO, enhancing its non-invasive vagus nerve stimulation (nVNS) technology. The first patent, U.S. Patent No. 11,511,109, relates to treating gastroparesis and functional dyspepsia with nVNS methods. The second patent, U.S. Patent No. 11,517,742, covers devices and methods for treating various disorders using nVNS. CEO Dan Goldberger highlighted that these patents broaden the application of nVNS therapy beyond migraines and cluster headaches, reflecting the company's commitment to innovation.
electroCore, Inc. (NASDAQ: ECOR) announced that its gammaCore Sapphire device has received a National Code Number (CNK) in Belgium. This unique identifier, issued by the Belgian Pharmaceutical Association, will facilitate the availability of gammaCore in pharmacies across Belgium. Iain Strickland, Senior Vice President at electroCore, emphasized that this development enhances patient access to their innovative vagus nerve stimulation therapy, which is used to treat various headache conditions. gammaCore is FDA cleared in the U.S. and CE-marked in the EU for several indications.
electroCore, Inc. (Nasdaq: ECOR) announced that CEO Dan Goldberger will hold one-on-one meetings at the Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum on November 17, 2022. electroCore focuses on bioelectronic medicine, aiming to enhance patient outcomes through non-invasive vagus nerve stimulation therapy. Their current treatments address several neurological conditions, including cluster headaches and migraines.
electroCore, Inc. (Nasdaq: ECOR) reported a 33% increase in third quarter 2022 revenue, totaling approximately $2.0 million, compared to $1.5 million in Q3 2021. Net loss widened to $5.5 million, up from $4.0 million year-over-year. Gross profit improved to $1.7 million with a gross margin of 87%, up from 76%. Total operating expenses rose to $7.3 million, up from $5.1 million. The company anticipates Q4 2022 revenue between $2.2 million and $2.3 million with cash usage of $4.0 million to $4.5 million.
electroCore (Nasdaq: ECOR) announced a distribution agreement with Joerns Healthcare to exclusively distribute the gammaCore Sapphire™, an FDA-cleared non-invasive device for treating headache pain. This collaboration aims to enhance patient access in managed care health systems and streamline billing processes. Joerns Healthcare's role is expected to facilitate broader usage of gammaCore therapy, benefiting primary headache sufferers. With this partnership, electroCore looks to expand its market presence and improve patient outcomes in the neurology sector.
electroCore, Inc. (Nasdaq: ECOR) has announced a strategic partnership with Joerns Healthcare for the distribution and billing of gammaCore Sapphire™, an FDA-cleared device for treating various headache types via vagus nerve stimulation. Joerns, known for streamlining healthcare delivery, aims to enhance access to electroCore's therapy within managed care systems. This collaboration is positioned to expand usage among patients suffering from primary headaches, aligning with electroCore's mission of improving patient outcomes using non-invasive treatments.
electroCore, Inc. (Nasdaq: ECOR) will release its third quarter financial results on November 3, 2022, after market hours. A conference call and webcast will follow at 4:30 PM EDT to discuss the results. The company focuses on bioelectronic medicine, utilizing non-invasive vagus nerve stimulation therapy for treating various neurological conditions, including migraines and cluster headaches.
FAQ
What is the current stock price of Electrocore (ECOR)?
What is the market cap of Electrocore (ECOR)?
What is electroCore's primary focus?
What conditions does gammaCore treat?
What is TAC-STIM used for?
How does electroCore generate revenue?
What sets electroCore apart from competitors?
What is Truvaga designed for?
What is electroCore's global presence?
What role does research play in electroCore's strategy?
What is Quell, and how does it fit into electroCore's portfolio?
What industries does electroCore serve?
